#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	9084	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2240	401.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1415	1415	C	470	C	462	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	16432	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3428	475.9	0	.	n	.	0	A20C	SNP	20	20	A	213	213	C	295	C	291	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	16432	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3428	475.9	0	.	n	.	0	T695C	SNP	695	695	T	888	888	C	502	C	494	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	16432	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3428	475.9	0	.	n	.	0	A1638G	SNP	1638	1638	A	1831	1831	G	520	G,A,T	506,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	16432	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3428	475.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2164	2164	C	476	C,G	462,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	16432	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3428	475.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2238	2238	A	506	A	503	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	16432	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3428	475.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	2790	2790	C	571	C,T	558,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1140	folP	855	855	100.0	folP.l15.c4.ctg.1	1526	74.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1098	1100	AGC	107;108;109	A;G;C	105;105;105	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3374	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3341	100.4	1	SNP	p	S91F	1	.	.	271	273	TTC	566	568	TTC	129;130;131	T;T,C;C	128;127,1;128	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3374	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3341	100.4	1	SNP	p	D95G	1	.	.	283	285	GGC	578	580	GGC	124;124;124	G;G,A;C	121;122,1;122	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	3374	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3341	100.4	1	SNP	p	G95N	0	.	.	283	285	GGC	578	580	GGC	124;124;124	G;G,A;C	121;122,1;122	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1026	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1350	75.6	0	.	p	.	0	F184L	NONSYN	550	552	TTC	928	930	TTG	104;104;106	T;T,G;G	103;101,1;103	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1026	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1350	75.6	1	SNP	p	G45D	0	.	.	133	135	GGC	511	513	GGC	110;111;108	G;G;C	106;108;104	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	516	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	962	53.5	0	.	n	.	0	A197.	DEL	197	197	A	582	582	A	119	A	115	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	2838	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2787	100.9	1	SNP	p	D86N	0	.	.	256	258	GAC	469	471	GAC	104;106;108	G;A;C	102;97;106	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	2838	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2787	100.9	1	SNP	p	R87W	0	.	.	259	261	CGT	472	474	CGT	105;104;104	C;G,A;T	103;101,1;100	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	2838	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2787	100.9	1	SNP	p	R87I	0	.	.	259	261	CGT	472	474	CGT	105;104;104	C;G,A;T	103;101,1;100	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	2838	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2787	100.9	1	SNP	p	S87R	1	.	.	259	261	CGT	472	474	CGT	105;104;104	C;G,A;T	103;101,1;100	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	2838	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2787	100.9	1	SNP	p	S88P	0	.	.	262	264	TCC	475	477	TCC	103;104;106	T;C;C	99;102;105	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2678	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2599	102.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1567	1569	GGC	153;148;148	G;G;C	150;145;144	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	2466	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2410	101.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1364	1366	GCA	133;133;134	G;C;A	131;130;130	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2466	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2410	101.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1367	1369	ATC	135;135;136	A;T;C	130;131;133	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2466	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2410	101.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1379	1381	GTG	130;128;127	G;T;G	127;124;123	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2466	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2410	101.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1379	1381	GTG	130;128;127	G;T;G	127;124;123	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2466	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2410	101.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1883	1885	ACC	111;111;114	A,G;C;CGG,CGGG	104,1;109;85,1	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2466	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2410	101.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1937	1939	GCG	113;112;114	G;C,G;G	108;98,1;109	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2466	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2410	101.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1937	1939	GCG	113;112;114	G;C,G;G	108;98,1;109	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2466	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2410	101.2	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2060	2062	AGC	107;108;108	A;G;C	106;107;107	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2466	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2410	101.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2069	2071	GGC	100;99;98	G;G;C	98;97;95	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	2466	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2410	101.2	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2087	2089	CCG	71;72;74	C,A;C;G	66,1;68;66	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	3336	ponA	2397	2397	99.92	ponA.l15.c30.ctg.1	3174	104.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1502	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1795	82.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	530	530	C	110	C,G	103,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	V258L	NONSYN	772	774	GTA	94	96	TTA	31;31;31	T;T;A	30;30;30	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	139	141	CAT	30;30;30	C;A;T	30;30;30	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	D274S	NONSYN	820	822	GAT	142	144	AGT	30;30;30	A;G;T	29;30;30	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	151	153	TAC	30;30;30	T;A;C	29;30;29	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	R307A	NONSYN	919	921	AGA	241	243	GCA	13;13;13	G;C;A	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	T311A	NONSYN	931	933	ACA	253	255	GCA	13;13;13	G;C;A	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	E312D	NONSYN	934	936	GAA	256	258	GAC	13;13;13	G;A;C	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	F314I	NONSYN	940	942	TTC	262	264	ATC	13;13;13	A;T;C	13;12;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	A316S	NONSYN	946	948	GCG	268	270	TCG	13;14;14	T;C;G	13;14;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	V318A	NONSYN	952	954	GTC	274	276	GCC	13;13;13	G;C;C	13;13;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	G319S	NONSYN	955	957	GGC	277	279	AGC	12;14;14	A;G;C	11;13;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	G320A	NONSYN	958	960	GGT	280	282	GCC	14;14;13	G;C;C	13;14;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	192	porB1a	984	271	91.88	porB1a.l15.c30.ctg.1	325	20.9	0	.	p	.	0	G322V	NONSYN	964	966	GGT	286	288	GTT	12;12;12	G;T;T	11;12;11	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1706	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1503	112.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	423	425	GAA	145;147;147	G;A;A	142;147;147	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1706	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1503	112.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	834	836	TCA	125;125;126	T;C;A	120;123;124	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1706	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1503	112.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	963	965	GTC	149;147;147	G;T;C	146;136;145	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1706	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1503	112.2	0	.	p	.	0	F222S	NONSYN	664	666	TTT	975	977	TCT	148;149;148	T;C;T	147;146;147	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1706	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1503	112.2	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1293	1295	GCA	137;140;141	G;C;A	136;138;138	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1706	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1503	112.2	1	SNP	p	G120K	1	.	.	358	360	AAG	669	671	AAG	109;109;111	A;A;G	105;105;107	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1706	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1503	112.2	1	SNP	p	D121N	0	.	.	361	363	GAC	672	674	GAC	113;110;110	G;A;C	107;106;107	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	1706	porB1b	1047	1047	99.24	porB1b.l15.c17.ctg.1	1503	112.2	1	SNP	p	A121D	1	.	.	361	363	GAC	672	674	GAC	113;110;110	G;A;C	107;106;107	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	5880	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4802	121.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	734	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1037	70.0	1	SNP	p	V57M	1	.	.	169	171	ATG	574	576	ATG	154;154;157	A;T;G	148;149;152	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
